BioLineRx (BLRX) director details extensive employee stock option grants

Rhea-AI Filing Summary

BioLineRx Ltd. director Barbara-Jean Anne Bormann-Kennedy filed an initial Form 3 reporting her employee stock option holdings. She lists multiple options to buy Ordinary Shares granted under the 2003 Amended and Restated Share Incentive Plan, with exercise prices such as $0.8370, $0.3560, and $0.0520 per share and expirations between 2026 and 2034. One grant for 2,055,000 underlying shares at an exercise price of $0.0520 per share expires on August 14, 2034; footnotes state that 856,200 of these options were vested as of October 1, 2024, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to her continued service.

Insider Trade Summary

10 transactions reported

Mixed 10 txns

Insider BORMANN-KENNEDY BARBARA-JEAN ANNE

Role Director

Type	Security	Shares	Price	Value
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--
holding	Employee Stock Option (Right to Buy)	--	--	--

Holdings After Transaction: Employee Stock Option (Right to Buy) — 49,800 shares (Direct)

Footnotes (1)

1. Options granted under the 2003 Amended and Restated Share Incentive Plan. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

BORMANN-KENNEDY BARBARA-JEAN ANNE

(Last) (First) (Middle)

BIOLINERX LTD.

2 HAMA'AYAN STREET

(Street)

MODII'N 7177871

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
BioLineRx Ltd. [ BLRX ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)(1)(2)	10/05/2016	07/05/2026	Ordinary Shares	49,800	$0.837	D
Employee Stock Option (Right to Buy)(1)(3)	10/05/2017	07/05/2027	Ordinary Shares	19,800	$0.92	D
Employee Stock Option (Right to Buy)(1)(4)	10/05/2018	07/05/2028	Ordinary Shares	19,800	$0.894	D
Employee Stock Option (Right to Buy)(1)(5)	10/02/2019	07/02/2029	Ordinary Shares	199,800	$0.356	D
Employee Stock Option (Right to Buy)(1)(6)	10/02/2020	07/02/2030	Ordinary Shares	79,800	$0.369	D
Employee Stock Option (Right to Buy)(1)(7)	10/02/2021	07/02/2031	Ordinary Shares	79,800	$0.388	D
Employee Stock Option (Right to Buy)(1)(8)	10/03/2022	07/03/2032	Ordinary Shares	1,080,000	$0.085	D
Employee Stock Option (Right to Buy)(1)(9)	10/03/2023	07/03/2033	Ordinary Shares	360,000	$0.081	D
Employee Stock Option (Right to Buy)(1)(10)	10/03/2024	07/03/2032	Ordinary Shares	360,000	$0.085	D
Employee Stock Option (Right to Buy)(11)	01/01/2025	08/14/2034	Ordinary Shares	2,055,000	$0.052	D

Explanation of Responses:

1. Options granted under the 2003 Amended and Restated Share Incentive Plan.

2. The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date.

3. The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date.

4. The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date.

5. The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date.

6. The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date.

7. The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date.

8. The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.

9. The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.

10. The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.

11. The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.

	/s/ Barbara- Jean Anne Bormann- Kennedy	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the BioLineRx (BLRX) Form 3 filing report for Barbara-Jean Anne Bormann-Kennedy?

The Form 3 reports Barbara-Jean Anne Bormann-Kennedy’s existing employee stock option holdings in BioLineRx. It lists several option grants to buy Ordinary Shares, detailing exercise prices, expiration dates, and vesting terms under the 2003 Amended and Restated Share Incentive Plan.

Are there any buy or sell transactions in the BioLineRx (BLRX) Form 3 for Bormann-Kennedy?

No new buy or sell transactions are shown; the entries are holdings of employee stock options. Each line reflects an existing option position, with no transaction code indicating open-market purchases or sales of BioLineRx Ordinary Shares in this filing.

What is the largest employee stock option grant reported for Bormann-Kennedy at BioLineRx (BLRX)?

The largest grant covers 2,055,000 underlying Ordinary Shares at an exercise price of $0.0520 per share. This option expires on August 14, 2034, with vesting spread between already vested options and future quarterly vesting installments.

How are the 2,055,000 BioLineRx (BLRX) options for Bormann-Kennedy vesting?

Footnotes state this grant was dated October 1, 2024, with 856,200 options vested as of appointment. The remaining 1,198,800 options vest in seven equal quarterly installments, subject to her continued service with BioLineRx on each vesting date.

Under which plan were Bormann-Kennedy’s BioLineRx (BLRX) options granted?

The options were granted under BioLineRx’s 2003 Amended and Restated Share Incentive Plan. The filing notes multiple annual grants since 2016, each fully vested as of its specified grant date, except the large 2024 grant with ongoing quarterly vesting.